Target: RANKL.
Clone: IK22/5.
Specificity: Anti-RANKL In Vivo Antibody - Low Endotoxin (IK22/5) recognizes an epitope on Mouse RANKL.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Background: RANKL (Receptor Activator for Nuclear Factor κ B Ligand), also known as TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and ODF (osteoclast differentiation factor), is a member of the tumor necrosis factor family cytokine. RANKL is essential for osteoclast formation, activation, and survival. RANKL through interaction with its receptor RANK can modulate matrix degradation and inflammation. RANKL and RANK have essential roles in lymph node formation, establishment of the thymic microenvironment, and development of a lactating mammary gland during pregnancy. Consequently, novel drugs specifically targeting RANK, RANKL, and their signaling pathways in osteoclasts are expected to revolutionize the treatment of various ailments associated with bone loss, such as arthritis, periodontal disease, cancer metastases, and osteoporosis.
Immunogen: Purified Recombinant Mouse RANKL (NSO-derived).
Concentration: 1.0 mg/ml.
Formulation: 0.01 M phosphate buffered saline (PBS) pH 7.2, 150 mM NaCl with no carrier protein, potassium or preservatives added.
Purity: >98% by SDS-PAGE and HPLC.
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 1%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
